GCG and diabetes mellitus: Since GLP-1 and GIP augment glucose-induced insulin release from pancreatic β-cells, suppresses glucagon secretion, and slows gastric emptying [57,58], incretins have been proposed as a potential therapeutic target for the treatment of patients with diabetes.